Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Steroid prophylaxis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
17SS-HSD1 and STS inhibitors
The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and / or steroid sulphatase enzymes and / or requiring the lowering of the endogenous 17β-estradiol concentration.
Owner:ABBVIE PHARMA GMBH
Composition for amelioration/prevention of adverse side effect in steroid therapy
InactiveUS20090291928A1Improvement of side effectsImproving and suppressing side effectOrganic active ingredientsBiocideDiseaseGlucocorticoid
Provided is a composition containing isoleucine, leucine and valine as active ingredients for improving or suppressing side effects associated with a steroid treatment and a composition for suppressing muscular atrophy-related gene. The composition improves or suppresses side effects in a steroid treatment such as muscular atrophy, muscular pain, arthritic pain, impaired glucose tolerance, decreased bone metabolism, impaired immunity, loss of appetite, body weight loss, fatigability and the like, and further suppresses muscular atrophy associated with various diseases. In addition, the composition suppresses muscular atrophy associated with promoted expression of muscular atrophy-related gene associated with glucocorticoid excess or renal failure pathology and the like. Therefore, the composition is effective form improving the QOL of patients.
Owner:EA PHARMA CO LTD
Novel compounds and their use in therapy
InactiveUS20050176742A1Suppress failureOrganic active ingredientsBiocideSteroid prophylaxisSteroidal hormones
Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17β-hydroxysteroid dehydrogenase enzymes.
Owner:SOLVAY PHARMA GMBH +1
A novel combination of epimedium-derived-flavonoids-fractions for prevention of steroid-induced osteonecrosis
The present invention relates to novel pharmaceutical compositions comprising Epimedium wushanense Ying extracts, their methods of preparation, and their use in inhibiting thrombosis and lipid deposition. Also provided by the present invention is a method of preventing or treating steroid-associated osteonecrosis with the use of the pharmaceutical composition of the present invention. The preparation method of the present invention is stable and provides reproducible results, both in small scale extraction and large scale extraction.
Owner:GUOYAOJITUAN TONGJITANG (GUIZHOU) PHARMA CO LTD
Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17.beta-hydroxysteroid dehydrogenase
ActiveUS20170081357A1Little and no inhibitory effectImprove the level ofOrganic active ingredientsSenses disorderDiseaseNitrogen
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
17β-HSD1 and STS inhibitors
Owner:ABBVIE PHARMA GMBH
Therapeutically active thiophenepyrimidinone compounds and their use
Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.
Owner:SOLVAY PHARM BV
Composition for amelioration/prevention of adverse side effect in steroid therapy
InactiveCN103120655AImprove side effectsImprovement or suppression of side effectsOrganic active ingredientsAntipyreticDiseaseSide effect
Owner:EA PHARMA CO LTD
Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17ss-hydroxysteroid dehydrogenase (17ss-HSD) such as 17ss-HSD type 1, type 2 or type 3 enzyme.
Owner:SOLVAY PHARMA GMBH
Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
InactiveUS7947463B2Increase volumeTherapy is simpleOrganic active ingredientsSerum immunoglobulinsPituitary glandSteroid prophylaxis
Compositions and methods that use the body's natural secretory immune system in a new way against steroid hormone responsive tumors of the breast and prostate, as well as other glandular / mucus epithelial tissues such as colon, ovary, endometrium, kidney, bladder, stomach, pancreas and secretory pituitary gland are provided. Also provided are new ways of identifying carcinogenic, or potentially carcinogenic, bacteria in a tissue or body fluid to provide better anti-cancer therapies and preventatives than have been available previously.
Owner:SIGNE BIOPHARMA
Method for treating or preventing steroid-induced glaucoma
InactiveUS20060212008A1Reduce eliminateInhibition formationCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsCross-linkIntegrin antagonist
An integrin antagonist reduces the occurrence of cross-linked actin network (CLAN) structures in cells of the trabecular meshwork. CLAN structures are associated with steroid-induced glaucoma. Reduction in CLAN structures is associated with increased aqueous humor outflow facility from the trabecular meshwork.
Owner:WISCONSIN ALUMNI RES FOUND
Compounds and their use in therapy
Owner:SOLVAY PHARMA GMBH +1
Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
ActiveUS20170081356A1Little and no inhibitory effectImprove the level ofSenses disorderNervous disorderDiseaseSteroid prophylaxis
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
Therapeutically active estratrienthiazole derivatives as hinibitors of 17 b-hydroxysteroid dehydrogenase, type 1
ActiveUS20170114090A1Little and no inhibitory effectImprove the level ofOrganic active ingredientsSenses disorderSteroid prophylaxisBULK ACTIVE INGREDIENT
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
17-beta HSD1 and STS Inhibitors
Substituted steroid compounds which represent selective inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and / or steroid sulfatase enzymes and / or requiring lowering of the endogenous 17β-estradiol concentration.
Owner:ABBVIE PHARMA GMBH
Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta-HSD) such as 17beta-HSD type 1, type 2 or type 3 enzyme.
Owner:SOLVAY PHARMA GMBH
Composition for amelioration/prevention of adverse side effect in steroid therapy
InactiveCN101600423AImprove side effectsImprovement or suppression of side effectsOrganic active ingredientsMuscular disorderDiseaseSide effect
Provided is a composition containing isoleucine, leucine and valine as active ingredients for improving or suppressing side effects associated with a steroid treatment and a composition for suppressing muscular atrophy-related gene. The composition improves or suppresses side effects in a steroid treatment such as muscular atrophy, muscular pain, arthritic pain, impaired glucose tolerance, decreased bone metabolism, impaired immunity, loss of appetite, body weight loss, fatigability and the like, and further suppresses muscular atrophy associated with various diseases. In addition, the composition suppresses muscular atrophy associated with promoted expression of muscular atrophy-related gene associated with glucocorticoid excess or renal failure pathology and the like. Therefore, the composition is effective form improving the QOL of patients.
Owner:AJINOMOTO CO INC
Therapeutically active steroidal derivatives
ActiveUS20180354984A1Little and no inhibitory effectImprove the level ofOrganic active ingredientsSteroidsSteroid prophylaxisBULK ACTIVE INGREDIENT
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
Compounds and their use in therapy
Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17β-hydroxysteroid dehydrogenase enzymes.
Owner:SOLVAY PHARM BV
Steroid ointment using physiological fat as base agent
InactiveCN108434090AImprove repair effectImprove repair abilityAerosol deliveryOintment deliveryTreatment effectSide effect
The invention discloses a steroid ointment using physiological fat as a base agent. The steroid ointment contains a base agent and steroid mixed with the base agent and having treatment effect, wherein the base agent is emulsifier-free physiological fat, and the physiological fat can be used for alleviating steroid induced side effects on the human body, is formed by imitating the component and the component of skin corneum layer fat, does not contain emulsifiers, does not contain additives harmful to the human body, has the structure extremely close to the skin, can excellently protect skin corneum layer, and can use the excellent moisturizing component, such that the side effect of damage on skin due to the use of steroid can be reduced and prevented through the moisturizing effect of the physiological fat and the repair effect of the corneum layer.
Owner:高一药品股份有限公司
Method for treating or preventing steroid-induced glaucoma
InactiveUS8152784B2Inhibition formationReduce and eliminate structureCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsCross-linkAqueous humor
An integrin antagonist reduces the occurrence of cross-linked actin network (CLAN) structures in cells of the trabecular meshwork. CLAN structures are associated with steroid-induced glaucoma. Reduction in CLAN structures is associated with increased aqueous humor outflow facility from the trabecular meshwork.
Owner:WISCONSIN ALUMNI RES FOUND
Therapeutically active steroidal derivatives
ActiveUS10717761B2Good metabolic stabilityOrganic active ingredientsSteroidsDiseaseSteroid prophylaxis
Owner:FORENDO PHARMA LTD
Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase
ActiveUS9663549B2Good metabolic stabilityOrganic active ingredientsSenses disorderDiseaseSteroid prophylaxis
Owner:FORENDO PHARMA LTD
Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1
ActiveUS10377791B2Good metabolic stabilityOrganic active ingredientsSenses disorderDiseaseSteroid prophylaxis
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
A novel combination of epimedium-derived-flavonoids-fractions for prevention of steroid-induced osteonecrosis
ActiveCN101641112BStable extractionStable implementation of extractionSugar derivativesMetabolism disorderSteroid prophylaxisThrombus
The present invention relates to novel pharmaceutical compositions comprising Epimedium wushanense Ying extracts, their methods of preparation, and their use in inhibiting thrombosis and lipid deposition. Also provided by the present invention is a method of preventing or treating steroid-associated osteonecrosis with the use of the pharmaceutical composition of the present invention. The preparation method of the present invention is stable and provides reproducible results, both in small scale extraction and large scale extraction.
Owner:GUOYAOJITUAN TONGJITANG (GUIZHOU) PHARMA CO LTD
Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase
This invention relates to novel substituted thiophenepyrimidinone derivatives and their use in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent diseases or disorder, such as steroid hormone dependent diseases or disorders requiring inhibition of 17beta-hydroxysteroid dehydrogenase enzymes.
Owner:SOLVAY PHARMA GMBH
Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
PendingUS20220041647A1Good metabolic stabilityOrganic active ingredientsSteroidsDiseaseSteroid prophylaxis
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and / or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
Owner:FORENDO PHARMA LTD
Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta-HSD) such as 17beta-HSD type 1, type 2 or type 3 enzyme.
Owner:SOLVAY PHARMA GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com